Apologies to others for arguing with the worse aspects of the contingent who think trials in collaboration with the Indonesian govt. in an affordable medical solution to a very common, and easily addressable, medical affliction with the government that overseas the fourth most populous nation in the world, is a poor business strategy. For those who understandably didn't read the report I sent the more ignorant of commentators on Indonesia, here is nice little chart for all.
Now apologies again for teaching many of you how to suck eggs (unavoidable when educating the few more ignorant alas) but of course whilst Indonesia perhaps not the first point of call for someone like recently successful Mesoblast in gaining approval in medical treatments that will cost hundreds of thousands of dollars (why of course MSB went for the onerous task of US approval), it is course a massive market for cheaper affordable medical solutions...like.....um I don't know, topical gels for (initially) mild infections.
Now Indonesia of course has shortcomings in its healthcare provision, but to tar it all with one brush assuming more basic health care is not more widely available, belies its strong recent push for universal healthcare, and indeed its achievement therein, in more basic affordable solutions - as R327 might of course be - as reflected in the following chart:
Oh look. Amoxicillin is already universally available in Indonesia, the country our esteemed friend assumes no one gets basic healthcare in. What's that? Amoxicllin is likely the first point of call in Indonesia in mild infections and might indeed be the first point of call in the DFU and other foot ulcer infections that Recce is trying to move in on with its gel (and has clearly evidenced likely better than) and its already universally available?
What's that? Yes, if R327 achieved even a tenth of penetration that Amoxicillin has in Indonesia it would be a massive market opportunity.
(20min delay)